相关实验视频
Updated: Jun 13, 2025
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.4K
适应性深度大脑刺激在帕金森病:一个德尔菲共识研究研究.
M Guidetti1, T Bocci1,2, M De Pedro Del Álamo3
1"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.
medRxiv : the preprint server for health sciences
|September 10, 2024
概括
适应性深度大脑刺激 (aDBS) 准备在十年内成为标准实践,为帕金森病提供更安全,更有效的治疗方法. 专家预计,aDBS将比传统的DBS提供更快,更稳定的症状控制.
科学领域:
- 神经科学是一个神经科学.
- 神经外科手术 神经外科手术
- 生物医学工程 生物医学工程
背景情况:
- 传统的深度大脑刺激 (cDBS) 已经显著发展,适应性方法 (aDBS) 代表了下一个前沿.
- 虽然aDBS设备可用,但临床应用和局限性的数据很少,需要专家协商一致.
- 从固定速率到按需心脏节拍的过渡为适应性神经调节的预期增长提供了历史上的平行.
研究的目的:
- 收集全球专家对适应性深度大脑刺激 (aDBS) 临床应用和技术挑战的意见.
- 指导和基础的临床开发和aDBS的实践神经系统疾病.
- 建立关于aDBS的安全性,有效性和未来发展轨迹的共识.
主要方法:
- 采用了Delphi方法,涉及5点的利克特比例问卷.
- 21名经验丰富的深度大脑刺激 (DBS) 临床医生参与了这项研究.
- 专家小组提交了42个涉及aDBS技术和临床方面的问题.
主要成果:
- 专家们达成共识,aDBS将在10年内融入临床实践.
- 专家小组同意aDBS的安全性,以及它可能比cDBS更快,更稳定的治疗反应.
- 预计aDBS将有利于帕金森病患者的,运动波动和动力障碍,尽管需要优化算法.
结论:
- 适应性深度大脑刺激 (aDBS) 被认为是安全的,并且有望在帕金森病 (PD) 患者中最大限度地提高有效性.
- 需要进一步的研究,特别是在算法开发和识别复杂PD症状的标志物方面.
- 预计aDBS将在未来几年进入广泛的临床实践,提高PD管理.
相关概念视频
01:24Parkinson's Disease: Treatment
237
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
237
01:15Parkinson's Disease: Overview
498
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
498